Veye Chest version 2

Aidence, an Amsterdam-based medical AI company, announced that Veye Chest version 2, a class IIa medical device, has obtained the CE mark. Veye Chest is now cleared to detect and characterize lung nodules in CT images in clinical practice across the EU.

Imaging plays a central role in the diagnosis of lung cancer, which often presents as pulmonary nodules on chest CT scans. Detecting and characterizing these nodules can be a trying and time-consuming task for radiologists who are expected to report nodules as small as 5mm. As a result of their small size and resemblance to normal lung structures, detecting these pulmonary nodules is often time-consuming and susceptible to errors.

Veye Chest leverages the power of artificial intelligence to assist radiologists in the detection and reporting of pulmonary nodules. It integrates seamlessly into the radiologists’ workflow. Veye Chest provides accurate, prompt and valuable nodule reports within radiologists’ existing workstations.

Building on the CE-marked software for the automated detection of pulmonary nodules, Veye Chest adds clinically approved features for fully automated nodule diameter and volume measurement, growth rate and composition. 

 

For more information: aidence.com


Additional Content

News | Radiology Imaging

Nov. 1, 2026 — GE HealthCare recently introduced Allia Celeo,* a ceiling-mounted image guiding system, at the ...

Time November 05, 2026
arrow
News | Radiology Imaging

Nov. 2, 2026 — Neurophet and RapidAI have partnered to integrate Neurophet’s advanced neurodegenerative brain imaging ...

Time November 04, 2026
arrow
News | Ultrasound Imaging

Nov. 3, 2026 — GE HealthCare has announced two new AI-assisted capabilities for its Vscan Air handheld ultrasound system ...

Time November 03, 2026
arrow
News | Ultrasound Imaging

Oct. 28, 2026 — Clarius Mobile Health has announced 30 specialized AI models are now integrated into Clarius App 13.1 ...

Time November 02, 2026
arrow
News | Women's Health

Oct. 29, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive ...

Time October 30, 2026
arrow
Subscribe Now